Clinical Trials
4 trialsNCT07217587 2026-05-08
EPIC
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT02965573 2024-08-28
A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness
argenx
Phase 2 Completed
NCT03770403 2023-07-14
ADAPT+
argenx
Phase 3 Completed
NCT03669588 2022-02-08
ADAPT
argenx
Phase 3 Completed